Early Clinical Outcomes With The Finevision® Pod F Gf Hydrophobic Trifocal And Trifocal Toric Intraocular Lens

To report the emerging clinical outcomes including complications, post-operative visual acuity, and refractive outcome data after small incision phacoemulsification surgery with implantation of the new FineVision/FineVision Pod F GF toric hydrophobic monofocal intraocular lens.

Optegra Eye Hospitals, UK

A retrospective audit was carried out of the clinical outcomes of 175 consecutive procedures carried out between January 2022 and December 2022 on 94 patients (mean age 64+/-8 years) following implantation of a FineVision IOL. Data were recorded in an electronic medical record at up to 3 months post-operatively. Procedures were excluded from the visual analysis if patients had reasons for a guarded visual prognosis such as amblyopia or maculopathy.

Results available from 169 eyes were eligible for inclusion.  No operative complications were recorded.  98% of distance targeted eyes achieved UDVA 20/40 or better and 51% of eyes achieved UDVA 20/20 or better.  95% of eyes had a SEQ within ±1.00D of target. 100% of patients achieved 20/40 or better and 65% achieved 20/20 or better binocularly. 165 eyes had near vision outcomes recorded of which 91% of patients achieved N8 or better and 73% achieved N5 or better. 

Our data show that the emerging clinical outcomes were favourable for this cohort overall.  Data collection and analysis of further metrics are ongoing and final follow up data will be reported in due course.